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1070-58 Ramipril Is Cost-Effective in Preventing Cardiovascular 
Events in Patients With Diabetes Mellitus 
Rita Ganaulv , Trivandrum V. Parasuraman, Wyeth Research, St. Davids, PA 
Background: Heart Outcomes Prevention Evaluation (HOPE) study and MICRO-HOPE 
sub-study showed significant mortality and morbidity benefits associated with the angio- 
tensin converting enzyme inhibitor, ramipril (AltaceTM), in the treatment of patients at 
high-risk for cardiovascular (CV) events. MICRO-HOPE, a randomized, placebo con- 
trolled study of ramipril, followed 3,577 high-risk diabetic patients. The primary outcome, 
a composite of myocardial infarction (Ml), stroke and CV death, was reduced from 19.6% 
in placebo to 15.3% in ramipril (relative risk reduction, 25%; p = OSX@l). Cardiac mortal- 
ity was also significantly reduced from 9.7% in placebo to 6.2% in ramipril (relative risk 
reduction, 37%; p = O.ooOl). With increasing cost containment pressures, there is a need 
to establish the cost-effectiveness of ramipril therapy in high-risk diabetic patients. 
Methods: A retrospective decision analysis was conducted to estimate cost-effectiveness 
ratio from a payer perspective using direct medical costs of clinical events from the litera- 
ture and efficacy data from the MICRO-HOPE study. Within-trial cost-effectiveness was 
estimated by the ratio of incremental expected cost of ramipril therapy to life years 
gained (LYG). LYG is the product of the ‘within-trial” difference in cardiac mortality rates 
and study duration. Efficacy data from MICRO-HOPE was used to populate the probabil- 
ities and compute the associated expected cost of fatal and non-fatal MI, stroke, cardiac 
mortality and other events. Drug costs were based on 1999 Red Book average wholesale 
price. All costs were discounted at 3% per year. 
Results: Over the trial period of 4 years, the base case discounted cost of ramipril ther- 
apy was $2,463 compared to $1.609 in placebo. This translates to a net incremental cost 
of $654 per patient on ramipril therapy. With a 3.5% absolute risk reduction in cardiac 
mortality, the incremental “within trial” cost per LYG was $4,671. Sensitivity analysis indi- 
cated that these estimates ranged from a cost per LYG of $4,464 to $4,764. 
Conclusion: Based on our estimates on cost per LYG we conclude that ramipril is cost- 
effective in preventing CV events in patients with Diabetes Mellitus. 
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1095-51 The Cyclooxygenase-2 Specific Inhibitor Valdecoxib Is 
Not Associated With an Increased Risk of 
Cardiovascular Thrombotlc Events in Arthritis Patients 
William B. White, Kenneth M. Verburg, Andrew Whelton, University of Connecticut, 
Farmington, CT, Pharmacia Corporation, Skokie, IL 
Background: There are concerns that the risk of serious thrombotic events may be higher 
with cyclooxygenase 
(COX).2 specific inhibitors than nonselective nonsteroidal anti-inflammatory drugs 
(NSAIDs). Valdecoxib. a new COX-2 specific inhibitor is approved in the US for treating 
osteoarthritis/rheumatoid arthritis (OAIRA; 10 mg qd) and primary dysmenorrhea (20 mg 
bid, PRN). Methods: The Incidence of serious thrombotic events (cardiac, cerebrovascu- 
lar and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled 
valdecoxib (lo-60 mg dally), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 600 
mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized. 6 to 52-week 
OAfRA trials. The incidence of events was determined in all patients (n = 7934), and 
aspirin (ASA; up to 325 mglday) and non-ASA users. Results: Crude and exposure- 
adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and pla- 
cebo (Table). The risk of serious thrombotic events was similar for each valdecoxib dos- 
age. Thrombotic risk was consistently higher for ASA-users than non-users (placebo 
1.4% vs 0%; valdecoxib 1.7% vs 0.2%; NSAlDs 1.9% YS 0.5%). The rates of events in 
ASA-users were similar for each treatment. Conclusion: Shorl and intermediate-term 
treatment with therapeutic and supratherapeutic valdacoxib doses was not associated 
with an increased incidence of thrombotic events relative to nonselective NSAlDs or pla- 
cebo in OAIRA Datients in controlled clinical trials. 
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Placebo Valdecoxib NSAlDs 
1142 4531 
161.1 1340.5 
” (%) IR’ ” (%) 
2 (0.2) 1.2 17 (0.4) 
1 (<O.l) 0.6 6 (0.1) 
0 (0.0) 0.0 1 (cO.1) 
1 (cO.1) 0.6 6 (0.2) 
0 (0.0) 0.0 1 (<O.l) 
2261 
655.7 
IR’ n (%) IR 
1.3 13 (0.6) 2.0 
0.4 7 (0.3) 1.1 
co.1 2 (<O.l) 0.3 
0.6 5 (0.2) 0.6 
<O.l 0 (0.0) 0.0 
‘IR= incidence rate, events par 100 patient-years. tA patient with more than one 
thrombotic event is counted only once in this overall incidence. No significant 
differences between groups. Sponsored by Pharmacia Corporation and Pfizer Inc 
1095-52 Increase in Risk Associated With a Statin Therapeutic 
Interchange Policy 
Peter Dumq Ltna Saad, Alison Tran. Anna Vichiendilokkul, Wayne State University, 
Detroit, MI, Harper University Hospital, Detroit, MI 
Therapeutic interchange (TI) is a common formulary management approach. It involves 
the substitution of one drug for another drug in its class at an equipotent dose. A TI policy 
for the statin class was implemented at our institution, with the preferred statin bemg sim- 
vastatin (SMV). We conducted the current study to assess the impact of this TI policy on 
the likelihood of drug interactions with SMV. 
Methods: Pharmacy records were reviewed for all inpatients prescribed a statin during 
the 3 months before and after the TI process was implemented. Patients who received 
any statin in combination wth an agent to produce a moderate or severe drug interaction 
had their inpatient medical chart reviewed. Drug interactions were classified as moderate 
and sevare, according to pharmacokinetic studies, reports of muscle-related toxicity, and 
FDA product labeling. Data was collected on interacting medications, statin dose, co- 
morbid conditions, muscle-related toxicity. 
Results: 1472 hospital admissions were evaluated in this study. Of the 744 patients 
admitted after implementation of the TI policy, 126 were exposed to moderate or severe 
drug interactions, compared to 59 exposures among the 726 patients that did not experi- 
ence TI (p-z 0.001). The average length of exposure to the interacting agent was 3 days. 
Twenty-nine patients in the post-T1 group were discharged on a regimen that included a 
moderate or severe drug interaction, compared to 17 patients in the pre-TI group (p= 
0.27) 
Conclusions: A TI program with SMV as the preferred agent resulted in doubling of expo- 
sure to moderate or severe drug interactions during hospitalization. This increase 
occured despite significant pharmacy and medical education regarding drug interactions 
with simvastatin. The increase in in-hospital drug interactions did not result in an increase 
in drug-interactions with discharge medications. We conclude that an inpatient TI pro- 
gram ,with SMV as the agent of choice, increases patients’ exposure to significant drug 
interactions. Institutions should carefully consider patient safety issues before embarking 
on such a program, as well as develop appropriate safety mechanisms to minlmize drug 
interactions. 
1095-53 Clinical Trials of Smoking Cessation Aids: A Meta- 
Analysis 
Jason R. Ludviq, Mark J. Eisenberg, Jewish General Hospital, Montreal, PQ, Canada 
Background: Although multiple clinical trials have examined smoking cessation aids, a 
systematic review of the efficacy of smoking cessation aids has yet to be performed. 
Methods: Forty-one clinical trials examining various smoking cessation aids were identi- 
fied. Eleven trials examined the nicotine patch (w4375); 11 trials nicottne gum (w3624); 
5 trials nkxtine inhaler (n=2752); 6 trials bupropion (n=4251); and 6 clinical trials behav- 
ioral therapy (n=ZlOO). Results: Each smoking cessation aid was associated with an 
absolute and relative increase in smoking abstinence rates compared wth placebo at 
both 6 and 12 months. Absolute increases in smoking abstinence range from 6.9% 
(behavioral therapy) to 13.2% (ncotine inhaler) at 6 months and from 5.2% (nicotine 
patch) to 11.6% (bupropion) at 12 months. Relative increases m smoking abstinence 
range from 19.6% (behavioral therapy) to 131% (nicotine Inhaler) at 6 months and from 
44.1% (behavioral therapy) to 167% (nicotine inhaler) at 12 months. Despite increases in 
smoking abstinence rates of over 10% for most smokmg cessation aids when compared 
with placebo, overall smoking relapse rates are still 70%-60%. 
Conclusion: Smoking cessation aids effect an approximate 10% increase in smoking 
abstinence at 6 and12 months compared with placebo. Although there is a clincally and 
statistically significant Increase in abstinence with smoking cessation atds, overall absti- 
nence rates are still very low. 
